PAT-DX1 Engineering Update
0
Patrys has today announced the completion of the first engineering run for its lead asset PAT-DX1. The purification of PAT-DX1…
$7.8m Capital Raise
Patrys has today announced a $7.8 million capital raising via a Placement and fully underwritten Rights Issue. These funds will…
Change of Company Secretary
Patrys is today welcoming the appointment of a new Company Secretary to our Senior Management Team, Stefan Ross, who was…
Important Notice – Fraudulent Emails
Patrys Ltd has been informed that fraudulent emails purporting to be sent from our Company are in circulation. The fraudulent…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30…
AusBiotech Conference | Australia Biotech Invest & Partnering Conference
Patrys CEO, Dr James Campbell, has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech…
Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model
Patrys today released the latest data from its completed proof-of-concept study demonstrating the potential of its full-sized deoxymab antibody, PAT-DX3,…
Patrys AGM – 5th Nov 2021
The Patrys Ltd team is pleased to invite you to a virtual webinar for our Annual General Meeting (AGM): WHEN:…
Proactive Lifesciences Webinar, 28 September 2021
Join Patrys’ CEO and Managing Director Dr James Campbell at 12pm AEST on Tuesday 28 September 2021 for the Proactive…
Bioshares | September 2021
An update on Patrys has been published in the latest issue of investor newsletter Bioshares this week. Titled ‘Patrys Demonstrates…